Repeated administration of the selective kappa-opioid receptor agonist U-69593 increases stimulated dopamine extracellular levels in the rat nucleus accumbens

Journal of Neuroscience Research

Volumn 84, Issue 2, 2006, Pages 450-459

  Fuentealba, José Antonio ^a   Gysling, Katia ^a   Magendzo, Karin ^a   Andrés, María Estela ^a  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

Author keywords

D2 autoreceptor; Microdialysis; Quinpirole

Indexed keywords

DOPAMINE AUTORECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; DOPAMINE TRANSPORTER; KAPPA OPIATE RECEPTOR AGONIST; N METHYL N [7 (1 PYRROLIDINYL) 1 OXASPIRO[4.5]DEC 8 YL]BENZENEACETAMIDE; POTASSIUM; QUINPIROLE; TYROSINE 3 MONOOXYGENASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOPAMINE RELEASE; DOPAMINERGIC NERVE CELL; DOSE RESPONSE; IMMUNOHISTOCHEMISTRY; LOCOMOTION; MALE; MICRODIALYSIS; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICAL ANALYSIS;

ANIMALS; BENZENEACETAMIDES; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; EXTRACELLULAR FLUID; IMMUNOHISTOCHEMISTRY; MALE; MICRODIALYSIS; MOTOR ACTIVITY; NEURONS; NUCLEUS ACCUMBENS; POTASSIUM; PYRROLIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, OPIOID, KAPPA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 33746433989     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.20890     Document Type: Article

References (44)

1. Acri JB, Thompson AC, Shippenberg TS. 2001. Modulation of pre- and postsynaptic dopamine D2 receptor function by the selective kappa-opioid receptor agonist U69593. Synapse 39:343-350.
2. Andrés ME, Gysling K, Bustos G. 1998. Differential regulation of dopamine release by N-methyl-D-aspartate receptors in rat striatum after partial and extreme lesions of the nigro-striatal pathway. Brain Res 797: 255-266.
3. Bishop JF, Mueller GP, Mouradian MM. 1994. Alternate 5′ exons in the rat brain-derived neurotrophic factor gene: differential patterns of expression across brain regions. Brain Res Mol Brain Res 26:225-232.
4. Buzas B, Cox BM. 1997. Quantitative analysis of mu and delta opioid receptor gene expression in rat brain and peripheral tissue using competitive polymerase chain reaction. J Neurosci 76:479-489.
5. Chefer VI, Czyzyk T, Bolan EA, Moron J, Pintar JE, Shippenberg TS. 2005. Endogenous kappa-opioid receptor systems regulate mesoaccumbal dopamine dynamics and vulnerability to cocaine. J Neurosci 25: 5029-5037.
6. Collins SL, D'Addario C, Izenwasser S. 2001. Effects of kappa-opioid receptor agonists on long-term cocaine use and dopamine neurotransmission. Eur J Pharmacol 426:25-34.
7. D'Addario C, Di Benedetto M, Izenwasser S, Candeletti S, Romualdi P. 2004. Differential time course of effects of kappa-opioid agonist treatment on dynorphin A levels and kappa-opioid receptor density. J Mol Neurosci 24:307-314.
8. Dalman F, O'Malley KL. 1999. κ-Opioid tolerance and dependence in culture of dopaminergic midbrain neurons. J Neurosci 19:5750-5757.
9. Di Chiara G, Imperato A. 1988a. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci U S A 85:5274-5278.
10. Di Chiara G, Imperato A. 1988b. Opposite effects of mu and kappa opiate agonists on dopamine release in the nucleus accumbens and in the dorsal caudate of freely moving rats. J Pharmacol Exp Ther 244:1067- 1080.
11. Dickinson SD, Sabeti J, Larson GA, Giardina K, Rubinstein M, Kelly MA, Grandy DK, Low MJ, Gerhardt GA, Zahniser NR. 1999. Dopamine D2 receptor-deficient mice exhibit decreased dopamine transporter function but no changes in dopamine release in dorsal striatum. J Neurochem 72:148-156.
12. Dugast C, Brun P, Sotty F, Renaud B, Suaud-Chagny MF. 1997. On the involvement of a tonic dopamine D2-autoinhibition in the regulation of pulse-to-pulse-evoked dopamine release in the rat striatum in vivo. Naunyn Schmiedebergs Arch Pharmacol 355:716-719.
13. Fuentealba JA, Forray MI, Gysling K. 2000. Chronic morphine treatment and withdrawal increase extracellular levels of norepinephrine in the rat bed nucleus of the stria terminalis. J Neurochem 75:741-748.
14. Gray AM, Rawls SM, Shippenberg TS, McGinty JF. 1999. The kappa-opioid agonist, U-69593, decreases acute amphetamine-evoked behaviors and calcium-dependent dialysate levels of dopamine and glutamate in the ventral striatum. J Neurochem 73:1066-1074.
15. Hamilton ME, Mele A, Pert A. 1992. Striatal extracellular dopamine in conscious vs. anesthetized rats: effects of chloral hydrate anesthetic on responses to drugs of different classes. Brain Res 597:1-7.
16. Heidbreder CA, Schenk S, Partridge B, Shippenberg TS. 1998. Increased responsiveness of mesolimbic and mesostriatal dopamine neurons to cocaine following repeated administration of a selective kappa-opioid receptor agonist. Synapse 30:255-262.
17. Hjelmstad GO, Fields HL. 2003. Kappa opioid receptor activation in the nucleus accumbens inhibits glutamate and GABA release through different mechanisms. J Neurophysiol 89:2389-2395.
18. Izenwasser S, Acri JB, Kunko PM, Shippenberg TS. 1998. Repeated treatment with the selective kappa opioid agonist U-69593 produces a marked depletion of dopamine D2 receptors. Synapse 30:275-283.
19. Kuzmin A, Semenova S, Gerris MA, Zvartau EE, Van Ree JM. 1997. Kappa-opioid receptor agonist U50488H modulates cocaine and morphine self-administration in drugs-naïve rats and mice. Eur J Pharmacol 321:265-271.
20. Kuzmin A, Sandin J, Terenius L, Ögren S. 2000. Dose- and time-dependent effects of KOR-opioid agonist on locomotor activity in mice. J Pharmacol Exp Ther 268:595-599.
21. 3H]U-69593 a highly selective ligand for the kappa-opioid receptor. Eur J Pharmacol 109:281-284.
22. Maisonneuve IM, Archer S, Glick SD. 1994. U-50488, a kappa opioid receptor agonits, attenuates cocaine-induced increases in extracellular dopamine in the nucleus accumbens of rats. Neurosci Lett 181:57-60.
23. Margolis EB, Hjelmstad GO, Bonci A, Fields HL. 2003. Kappa-opioid agonists directly inhibit midbrain dopaminergic neurons. J Neurosci 23: 9981-9986.
24. Mello NK, Negus S. 2000. Interaction between kappa opioid agonist and cocaine. Preclinical studies. Ann N Y Acad Sci 909:105-132.
25. Meshul CK, McGinty JF. 2000. Kappa opioid receptor immunoreactivity in the nucleus accumbens and caudate-putamen is primarily associated with synaptic vesicles in axons. Neuroscience 96:91-99.
26. Mitrovic I, Napier TC. 2002. Mu and kappa opioid agonists modulate ventral tegmental area input to the ventral pallidum. Eur J Neurosci 15: 257-268.
27. Mortensen OV, Amara SG. 2003. Dynamic regulation of the dopamine transporter. Eur J Pharmacol 479:159-170.
28. Ojeda V, Fuentealba JA, Galleguillos D, Andrés ME. 2003. Rapid increase of Nurr1 expression in the substantia nigra after 6-hydroxydopamine lesion in the striatum of the rat. J Neurosci Res 73:686-697.
29. Paxinos G, Watson C. 1986. The rat brain in stereotaxic coordinates, 2nd ed. Sydney: Academic Press.
30. Perreault ML, Graham D, Bisnaire L, Simms J, Hayton S, Szechtman H. 2005. Kappa-opioid agonist U69593 potentiates locomotor sensitization to the D2/D3 agonist quinpirole: pre- and postsynaptic mechanisms. Neuropsychopharmacology (in press).
31. Ronken E, Mulder AH, Schoffelmeer AN. 1994. Chronic activation of mu- and kappa-opioid receptors in cultured catecholaminergic neurons from rat brain causes neuronal supersensivity without receptor desensitization. J Pharmacol Exp Ther 268:595-599.
32. Rouge-Pont F, Usiello A, Benoit-Marand M, Gonon F, Piazza PV, Borrelli E. 2002. Changes in extracellular dopamine induced by morphine and cocaine: crucial control by D2 receptors. J Neurosci 22: 3293-3301.
33. Santibañez M, Gysling K, Forray MI. 2005. Adrenalectomy decreases corticotropin-releasing hormone gene expression and increases noradrenaline and dopamine extracellular levels in the rat lateral bed nucleus of the stria terminalis. J Neurosci Res 81:140-152.
34. Schenk S, Partridge B, Shippenberg TS. 1999. U69593, a kappa-opioid agonist, decreases cocaine self-administration and decreases cocaine-produced drug-seeking. Psychopharmacology 144:339-346.
35. Schmitz Y, Benoit-Marand M, Gonon F, Sulzer D. 2003. Presynaptic regulation of dopaminergic neurotransmission. J Neurochem 87:273-289.
36. Sotomayor R, Forray MI, Gysling K. 2005. Acute morphine administration increases extracellular DA levels in the rat lateral septum by decreasing the GABAergic inhibitory tone in the ventral tegmental area. J Neurosci Res 81:132-139.
37. Spanagel R, Herz A, Shippenberg TS. 1990. The effects of opioid peptides on dopamine release in the nucleus accumbens: an in vivo microdialysis study. J Neurochem 55:1734-1740.
38. Spanagel R, Herz A, Shippenberg TS. 1992. Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway. Proc Natl Acad Sci U S A 89:2046-2050.
39. Svingos AL, Chavkin C, Colago EE, Pickel VM. 2001. Major coexpression of kappa-opioid receptors and the dopamine transporter in nucleus accumbens axonal profiles. Synapse 42:185-192.
40. Thompson AC, Zapata A, Justice JB Jr, Vaughan RA, Sharpe LG, Shippenberg TS. 2000. Kappa-opioid receptor activation modifies dopamine uptake in the nucleus accumbens and opposes the effects of cocaine. J Neurosci 20:9333-9340.
41. Torres GE, Carneiro A, Seamans K, Fiorentini C, Sweeney A, Yao WD, Caron MG. 2003. Oligomerization and trafficking of the human dopamine transporter. Mutational analysis identifies critical domains important for the functional expression of the transporter. J Biol Chem 278: 2731-2739.
42. Vecchiola A, Collyer P, Figueroa R, Labarca R, Bustos G, Magendzo K. 1999. Differential regulation of mu-opioid receptor mRNA in the nucleus accumbens shell and core accompanying amphetamine behavioral sensitization. Brain Res Mol Brain Res 69:1-9.
43. Xi ZX, Fuller SA, Stein EA. 1998. Dopamine release in the nucleus accumbens during heroin self-administration is modulated by kappa opioid receptors: an in vivo fast-cyclic voltammetry study. J Pharmacol Exp Ther 284:151-161.
44. You ZB, Herrera-Marschitz M, Terenius L. 1999. Modulation of neurotransmitter release in the basal ganglia of the rat brain by dynorphin peptides. J Pharmacol Exp Ther 290:1307-1315.